Guretolimod is primarily investigated for its immunomodulatory properties, particularly in the context of cancer immunotherapy. It functions as a TLR8 agonist, activating immune cells such as dendritic cells and monocytes, which enhances the body’s anti-tumor immune response. This makes it a candidate for use in combination therapies with checkpoint inhibitors or other immunotherapeutic agents. Its application is being explored in preclinical and clinical settings for solid tumors, where localized or systemic immune activation is desired. Additionally, Guretolimod has shown potential in vaccine adjuvants, boosting the efficacy of therapeutic vaccines by promoting stronger T-cell responses.